(Q53641322)

16 May 2018

title

Enhanced viral and tumor immunity with intranodal injection of canary pox viruses expressing the melanoma antigen, gp100. (English)

1 reference

16 May 2018

author name string

David E Spaner

1

1 reference

16 May 2018

Igor Astsaturov

2

1 reference

16 May 2018

Thorsten Vogel

3

1 reference

16 May 2018

Teresa Petrella

4

1 reference

16 May 2018

Ileana Elias

5

1 reference

16 May 2018

Susan Burdett-Radoux

6

1 reference

16 May 2018

Shailendra Verma

7

1 reference

16 May 2018

Neill Iscoe

8

1 reference

16 May 2018

Paul Hamilton

9

1 reference

16 May 2018

Neil L Berinstein

10

1 reference

16 May 2018

language of work or name

English

0 references

publication date

1 February 2006

1 reference

16 May 2018

number of pages

10

1 reference

inferred from page(s)

published in

Cancer

1 reference

16 May 2018

volume

106

1 reference

16 May 2018

issue

4

1 reference

16 May 2018

page(s)

890-899

1 reference

16 May 2018

MAGE-A1-, MAGE-A10-, and gp100-derived peptides are immunogenic when combined with granulocyte-macrophage colony-stimulating factor and montanide ISA-51 adjuvant and administered as part of a multipeptide vaccine for melanoma

cites work

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.21669

Progress on new vaccine strategies for the immunotherapy and prevention of cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.21669

7 January 2021

A listing of human tumor antigens recognized by T cells

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.21669

7 January 2021

Vaccination of melanoma patients with peptide- or tumor lysate-pulsed dendritic cells

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.21669

7 January 2021

Granulocyte-macrophage-colony-stimulating factor added to a multipeptide vaccine for resected Stage II melanoma

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.21669

7 January 2021

Gene therapy progress and prospects: adenoviral vectors

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.21669

7 January 2021

Poxvirus-based vaccine candidates for cancer, AIDS, and other infectious diseases.

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.21669

7 January 2021

Safety profile of recombinant canarypox HIV vaccines

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.21669

7 January 2021

Human safety and immunogenicity of a canarypox-rabies glycoprotein recombinant vaccine: an alternative poxvirus vector system

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.21669

7 January 2021

A prime-boost approach to HIV preventive vaccine using a recombinant canarypox virus expressing glycoprotein 160 (MN) followed by a recombinant glycoprotein 160 (MN/LAI). The AGIS Group, and l'Agence Nationale de Recherche sur le SIDA.

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.21669

7 January 2021

Duration of TCR stimulation determines costimulatory requirement of T cells

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.21669

7 January 2021

CD4 T cells and their role in antitumor immune responses

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.21669

7 January 2021

Peptide based cytotoxic T-cell vaccines; delivery of multiple epitopes, help, memory and problems.

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.21669

7 January 2021

Immunologic and clinical outcomes of vaccination with a multiepitope melanoma peptide vaccine plus low-dose interleukin-2 administered either concurrently or on a delayed schedule

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.21669

7 January 2021

Immunologic and therapeutic evaluation of a synthetic peptide vaccine for the treatment of patients with metastatic melanoma

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.21669

7 January 2021

New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.21669

7 January 2021

Neutralizing antiviral antibody responses

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.21669

7 January 2021

Intranodal Administration of Peptide-Pulsed Mature Dendritic Cell Vaccines Results in Superior CD8+T-Cell Function in Melanoma Patients

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.21669

7 January 2021

Phase I study of intranodal delivery of a plasmid DNA vaccine for patients with Stage IV melanoma

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.21669

7 January 2021

Reduction of otherwise remarkably stable virus-specific cytotoxic T lymphocyte memory by heterologous viral infections.

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.21669

7 January 2021

gp100(209-2M) peptide immunization of human lymphocyte antigen-A2+ stage I-III melanoma patients induces significant increase in antigen-specific effector and long-term memory CD8+ T cells

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.21669

7 January 2021

Final version of the American Joint Committee on Cancer staging system for cutaneous melanoma

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.21669

7 January 2021

Toxicity and response criteria of the Eastern Cooperative Oncology Group

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.21669

7 January 2021

Identifiers

DOI

10.1002/CNCR.21669

1 reference

16 May 2018

1 reference

16 May 2018